Inovio Pharmaceuticals Inc (NYSEMKT:INO) announces results of peer-review

Posted by Lynn Eisler July 11, 2013 0 Comment 2741 views

Inovio Pharmaceuticals Inc (NYSEMKT:INO) announced the peer-reviewed publication of results of its PENNVAX-B preventive HIV DNA vaccine undergoing phase I clinical trials namely HVTN 070 and HVTN 080 which are delivered with a DNA adjuvant and with or without Inovio’s proprietary CELLECTRAelectroporation delivery device.

Inovio’s HIV DNA vaccine along with the CELLECTRA device significantly increased the number of responders which produces CD4 and CD8 T-cell’s strong and durable responses in humans. CD4 and CD8 T-cells plays an important role in the cellular immunity, however, CD8 T-cells is much more important as they fight against cancers and chronic infectious diseases. It was a challenge for the HIV researchers to achieve a robust CD8 T-cell response in the patients undergoing the clinical trial. The PENNVAX-B vaccine successfully generated CD8 T-cell responses with significant magnitude.

Dr. J. Joseph Kim, Inovio’s President and CEO said that their two product candidates in two different disease indications are the best-in-class T-cell responses. He also said that the results as per the clinical trial prove not only the robust HIV-specific T-cell production achieved with next-generation vaccine technology, but also defines the significant impact of their CELLECTRA electroporation technology in increasing targeted immune responses.

The company has incorporated the knowledge of single-clade PENNVAX-B program into the designing of their multi-clade PENNVAX®-GP vaccine which is now the leading preventive and therapeutic vaccine that broadly targets global HIV strains. PENNVAX-GP was developed through a $25 million contract with the NIAID; the clinical study of PENNVAX-GP will also be conducted by the HVTN.

The stock of the company has significantly increased by 72.94% in its two days of trading. The stock of the company closed at $1.47 showing an increase of 24.58%. The company’s average volume of trade was only 2.54 million as compared to the trade volume of 32.90 million in its previous day’s trading.

About Lynn Eisler

Lynn Eisler is a national news reporter focusing on economic issues, data analysis and the financial health of state and local governments. Lynn has been honored with the H.L. Mencken Award for Investigative Reporting, the Champion of Justice Award for reporting on the drug war, and the John Hancock Award for business reporting. Lynn was also a Knight Medical School Fellow at the University of Michigan.

View all post by Lynn Eisler Visit author's website

Write Your Comment